Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - Stifel has reiterated its Buy rating on Boston Scientific (NYSE:BSX) with a price target of $125.00, citing confidence in the company’s growth outlook. The stock, currently trading at $104.17 and near its 52-week high of $109.50, has shown strong momentum with a 12.76% return over the past year. According to InvestingPro data, analysts maintain a strong buy consensus, with price targets ranging from $99 to $140.
The research firm expressed strong belief that Boston Scientific’s 2026-2028 double-digit revenue growth outlook is "highly credible and achievable," with the company’s third-quarter 2025 performance reinforcing this confidence. This outlook is supported by the company’s impressive 21.44% revenue growth in the last twelve months and robust gross profit margin of 68.04%. InvestingPro analysis reveals 15+ additional insights about Boston Scientific’s financial health and growth potential.
Stifel highlighted Boston Scientific’s innovation, clinical data catalysts, opportunities in key focus markets, and M&A capacity as factors positioning the company for sustainable double-digit growth.
Looking ahead to 2026, Stifel models approximately 11% organic revenue growth for Boston Scientific, driven by "positive broad-based growth performance" across business lines, with particularly strong contributions expected from Watchman and Electrophysiology divisions.
The firm currently projects modest 2026 operating margin expansion of approximately 15 basis points compared to expectations of 50+ basis points improvement in later years as Boston Scientific annualizes current tariff impacts.
In other recent news, Boston Scientific reported impressive third-quarter earnings, with revenue reaching $5.065 billion, surpassing consensus estimates of $4.969 billion. The company achieved a 20.3% reported growth and a 15.3% organic growth, alongside adjusted earnings per share of $0.75, exceeding the forecasted $0.71. BTIG has reiterated its Buy rating for Boston Scientific, maintaining a price target of $132.00 following the company’s strong earnings performance. Meanwhile, Evercore ISI raised its price target for the company to $113.00 from $110.00, keeping an Outperform rating on the stock. This decision was influenced by Boston Scientific’s robust performance across multiple business segments, despite previous concerns about potential share losses in the electrophysiology segment. The company’s strategic product launches and operational sales growth were key drivers of its success this quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.